Anchiano Therapeutics, a Phase 3 biotech developing therapies for early-stage bladder cancer, raised $31 million by offering 2.7 million ADSs at $11.50, below the expected price of $14.55.
At $11.50, Anchiano Therapeutics would command a market cap of $78 million. The company previously filed to raise $35 million by offering 2.4 million ADSs at $14.55.
Anchiano Therapeutics plans to list on the Nasdaq under the symbol ANCN. Oppenheimer & Co. acted as a lead manager on the deal.
The article Micro-cap biotech Anchiano Therapeutics prices IPO at $11.50, below the expected price originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
